Thursday May 24 | BioSpace
XenoPort, Inc. Submits Investigational New Drug Application for...
SANTA CLARA, Calif.-- --XenoPort, Inc. announced today that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration to begin clinical studies of XP23829 as a potential treatment for relapsing-remitting multiple sclerosis .
Monday's NASDAQ Winners: GOLF, CSBC, XNPT, SYNC
May 15, 2012 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Monday, May 14.
XenoPort, Inc. Reports First Quarter Financial Results
HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia SANTA CLARA, Calif.-- --XenoPort, Inc.
XenoPort to Present at the Deutsche Bank Annual Health Care Conference
SANTA CLARA, Calif. -- -- XenoPort, Inc. announced today that it will provide access via the World Wide Web to its presentation at the Deutsche Bank 37th Annual Health Care Conference.